Dr. Laura Elizabeth Melnick, MD

Dr. Melnick practices at NYU Langone - Tisch Hospital in New York, New York.

Dr. Melnick's NPI, 1679910335, was assigned on June 3, 2013. Dr. Melnick graduated from Perelman School of Medicine - Philadelphia in 2013. Dr. Melnick holds New York license 284900.

Dr. Melnick's primary practice is NYU Langone - Tisch Hospital, at 550 1st Ave, New York, NY 10016 in New York County. The practice phone is (212) 263-1481.

Dr. Melnick's primary practice is NYU Langone - Tisch Hospital in New York, New York. Dr. Melnick is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Melnick to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Melnick practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Melnick's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Melnick is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Melnick's licenses on file in 3 states: New York, New Jersey and Pennsylvania.

Dmand AI lists benign or precancerous skin growths, contact dermatitis, itchy rashes, rash, scalp rash, skin cyst and skin discoloration among the conditions Dr. Melnick treats.

CMS data shows 348 Medicare services from Dr. Melnick across 9 procedure codes in 2024, for 155 Medicare patients. Medicare paid $27,182 for them. Every service was in an office.

CMS counts 155 Medicare patients who saw Dr. Melnick in 2024. The largest group is 75 to 84, with 66 patients. 75% of them have high cholesterol, and 62% have high blood pressure. 14% are also on Medicaid. Their average risk score is 1.28, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Melnick's median patient age at 20, with 60% women.

In 2024, Dr. Melnick wrote 411 Medicare Part D claims for 108 patients. 95% of them were for generic drugs. CMS names the drug for 305 of them, across 8 drugs with 11 or more claims each, at $13,685 in total drug cost. In 2023, CMS named 234 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Melnick for performance year 2024, reported through an alternative payment model (APM). Dr. Melnick accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Melnick as offering telehealth. CMS counts 81 procedures of removal of skin lesions by Dr. Melnick, more than 74% of the clinicians it reports for that procedure.

Dmand AI links 19 papers to Dr. Melnick, published from 2014 to 2024. 2020 was the busiest year, with 4. The most frequent topics are Skin Diseases, Diagnosis, Differential and COVID-19. Dr. Melnick has published most often in Pediatr Dermatol. Dr. Melnick's most frequent co-authors are Nooshin Ketabchi Brinster, MD, Kimberly D. Morel, MD and Fludiona Naka, MD, MPH.

CMS Open Payments shows 3 general payments to Dr. Melnick from 2 drug and device companies from 2017 to 2022. Food and beverage make up the largest share, 89% of the total. Nuvasive, Inc. paid the most, $229.

Dr. Melnick graduated from Perelman School of Medicine - Philadelphia in 2013.

Dr. Melnick is in network with 16 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.